$5.00
0.30% today
NYSE, Nov 12, 07:19 pm CET
ISIN
US67080N1019
Symbol
NUVB

Nuvation Bio Inc - Ordinary Shares - Class A Stock price

$4.98
+1.30 35.33% 1M
+2.83 131.63% 6M
+2.32 87.22% YTD
+1.97 65.45% 1Y
+2.98 149.00% 3Y
-5.21 51.13% 5Y
-5.02 50.20% 10Y
-5.02 50.20% 20Y
NYSE, Closing price Tue, Nov 11 2025
+0.34 7.33%
ISIN
US67080N1019
Symbol
NUVB
Industry

Key metrics

Basic
Market capitalization
$1.7b
Enterprise Value
$1.4b
Net debt
positive
Cash
$549.1m
Shares outstanding
342.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
64.0 | 56.8
EV/Sales
51.1 | 45.3
EV/FCF
negative
P/B
5.3
Financial Health
Equity Ratio
85.8%
Return on Equity
-122.5%
ROCE
-43.7%
ROIC
-765.3%
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
$26.8m | $30.2m
EBITDA
$-231.6m | -
EBIT
$-233.0m | $-249.5m
Net Income
$-217.5m | $-228.4m
Free Cash Flow
$-198.3m
Growth (TTM | estimate)
Revenue
1,138.4% | 283.3%
EBITDA
-72.9% | -
EBIT
-73.3% | -48.9%
Net Income
59.1% | 59.8%
Free Cash Flow
-99.6%
Margin (TTM | estimate)
Gross
54.3%
EBITDA
-865.7% | -
EBIT
-871.0%
Net
-813.1% | -757.2%
Free Cash Flow
-741.2%
More
EPS
$-0.6
FCF per Share
$-0.6
Short interest
37.8%
Employees
220
Rev per Employee
$40.0k
Show more

Is Nuvation Bio Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,033 stocks worldwide.

Nuvation Bio Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Nuvation Bio Inc - Ordinary Shares - Class A forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Nuvation Bio Inc - Ordinary Shares - Class A forecast:

Buy
93%
Hold
7%

Financial data from Nuvation Bio Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
27 27
1,138% 1,138%
100%
- Direct Costs 12 12
328% 328%
46%
15 15
2,173% 2,173%
54%
- Selling and Administrative Expenses 137 137
183% 183%
514%
- Research and Development Expense 110 110
29% 29%
412%
-232 -232
73% 73%
-866%
- Depreciation and Amortization 1.42 1.42
173% 173%
5%
EBIT (Operating Income) EBIT -233 -233
73% 73%
-871%
Net Profit -217 -217
59% 59%
-813%

In millions USD.

Don't miss a Thing! We will send you all news about Nuvation Bio Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nuvation Bio Inc - Ordinary Shares - Class A Stock News

Positive
Seeking Alpha
5 days ago
Nuvation Bio is demonstrating strong early commercial success with Ibtrozi, its newly FDA-approved therapy for ROS1-positive non-small cell lung cancer. NUVB reported 204 new patients for Ibtrozi in the latest quarter, supporting a robust revenue trajectory and validating the product's market potential. A conservative revenue projection supports NUVB's current market cap. The value of ex-US mar...
Neutral
Seeking Alpha
9 days ago
Nuvation Bio Inc. ( NUVB ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Robert DeVita David Hung - Founder, President, CEO & Chairman Colleen Sjogren - Chief Commercial Officer Philippe Sauvage - CFO & Principal Financial Officer Conference Call Participants Kaveri Pohlman - Clear Street LLC Farzin Haque - Jefferies LLC, Research Division Soumit Roy - JonesTrading Ins...
Neutral
Business Wire
9 days ago
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “We are thrilled that 204 new patients have received IBTROZI during our first full quarter as a commercial-stage company,” sai...
More Nuvation Bio Inc - Ordinary Shares - Class A News

Company Profile

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Head office United States
CEO David Hung
Employees 220
Founded 2018
Website www.nuvationbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today